Literature DB >> 8476069

Interleukin-8: an important chemoattractant in sputum of patients with chronic inflammatory airway diseases.

J B Richman-Eisenstat1, P G Jorens, C A Hébert, I Ueki, J A Nadel.   

Abstract

Sputum from patients with cystic fibrosis, bronchiectasis, and chronic bronchitis contains neutrophils and neutrophil proteases, which have been implicated in the pathophysiology of mucus hypersecretion in airways. We asked whether interleukin-8 (IL-8), a potent neutrophil chemoattractant, might be involved in recruiting neutrophils into airways of patients with cystic fibrosis, bronchiectasis, and chronic bronchitis. We found significant neutrophil chemotactic activity in sputum obtained from these patients. The IL-8 concentrations that we measured in sputum of patients with cystic fibrosis (7.1 +/- 1.0 x 10(-9) M, mean +/- SE), bronchiectasis (9.6 +/- 2.9 x 10(-9) M), and chronic bronchitis (2.8 +/- 1.0 x 10(-9) M) have been reported to cause significant chemotaxis in vitro and in airways in vivo, whereas concentrations measured in induced sputum from healthy subjects (1.1 +/- 0.3 x 10(-10) M) do not. A monoclonal antibody to IL-8 significantly inhibited the chemotactic activity in patients' sputum by 75-98%, but not in induced sputum from healthy subjects (9%). We conclude that IL-8 is an important chemotactic factor in sputum of patients with cystic fibrosis, bronchiectasis, and chronic bronchitis, and we suggest that IL-8 accounts, at least in part, for neutrophil recruitment into airways of patients with these diseases.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8476069     DOI: 10.1152/ajplung.1993.264.4.L413

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  74 in total

1.  The extract of Cordyceps sinensis inhibited airway inflammation by blocking NF-κB activity.

Authors:  Ya-Ling Chiou; Ching-Yuang Lin
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

2.  Elevated miR-155 promotes inflammation in cystic fibrosis by driving hyperexpression of interleukin-8.

Authors:  Sharmistha Bhattacharyya; Nagaraja S Balakathiresan; Clifton Dalgard; Usha Gutti; David Armistead; Cathy Jozwik; Meera Srivastava; Harvey B Pollard; Roopa Biswas
Journal:  J Biol Chem       Date:  2011-01-31       Impact factor: 5.157

3.  IL-17-induced cytokine release in human bronchial epithelial cells in vitro: role of mitogen-activated protein (MAP) kinases.

Authors:  M Laan; J Lötvall; K F Chung; A Lindén
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

4.  Mono ADP-ribosylation inhibitors prevent inflammatory cytokine release in alveolar epithelial cells.

Authors:  Mariangela Del Vecchio; Enrico Balducci
Journal:  Mol Cell Biochem       Date:  2007-12-09       Impact factor: 3.396

5.  Global genomic analysis of AlgU (sigma(E))-dependent promoters (sigmulon) in Pseudomonas aeruginosa and implications for inflammatory processes in cystic fibrosis.

Authors:  Aaron M Firoved; J Cliff Boucher; Vojo Deretic
Journal:  J Bacteriol       Date:  2002-02       Impact factor: 3.490

6.  Transcriptional and post-transcriptional regulation of interleukin-8.

Authors:  L H Villarete; D G Remick
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

Review 7.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 8.  Monitoring inflammation in CF. Cytokines.

Authors:  Scott D Sagel; Frank J Accurso
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

Review 9.  The role of inflammation in the pathophysiology of CF lung disease.

Authors:  James F Chmiel; Melvin Berger; Michael W Konstan
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

10.  Contribution of Burkholderia cenocepacia flagella to infectivity and inflammation.

Authors:  Teresa A Urban; Adam Griffith; Anastasia M Torok; Mark E Smolkin; Jane L Burns; Joanna B Goldberg
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.